<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01236040</url>
  </required_header>
  <id_info>
    <org_study_id>114371</org_study_id>
    <nct_id>NCT01236040</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old</brief_title>
  <official_title>Immunogenicity and Safety Study of GSK Biologicals' Cell Culture Derived Pandemic Influenza Vaccines GSK2590066A and GSK2592984A Administered to Healthy Adults 18 - 49 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate&#xD;
      vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2010</start_date>
  <completion_date type="Actual">August 20, 2012</completion_date>
  <primary_completion_date type="Actual">September 6, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity with respect to components of the investigational vaccine Day 0</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity with respect to components of the investigational vaccine Day 42</measure>
    <time_frame>Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Grade 3 injection site pain</measure>
    <time_frame>During a 7-day follow-up period (Day 0 to 6) after any vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of each solicited local symptom</measure>
    <time_frame>During a 7-day follow-up period (Day 0 to 6) after any vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of each solicited general symptom</measure>
    <time_frame>During a 7-day follow-up period (Day 0 to 6) after any vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited adverse events (AEs)</measure>
    <time_frame>Within 21 days (Day 0 to 20) after any vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of AEs with medically attended visits (MAEs)</measure>
    <time_frame>During the entire study period (from Day 0 to Month 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and relationship to vaccination of (potential) immune mediated diseases (pIMDs)</measure>
    <time_frame>During the entire study period (from Day 0 to Month 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and relationship to vaccination of serious adverse events (SAEs)</measure>
    <time_frame>During the entire study period (from Screening to Month 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse pregnancy outcomes</measure>
    <time_frame>During the entire study period (from Day 0 to Month 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical safety laboratory abnormalities</measure>
    <time_frame>At Days 7, 28 and at Month 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the investigational vaccine in terms of hemagglutinin Inhibition (HI) antibodies</measure>
    <time_frame>At Days 0, 21, and 42 and Months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the investigational vaccine in terms of microneutralization (MN) antibodies</measure>
    <time_frame>Days 0, 21, and 42 and Months 6 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">521</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 2 doses of a formulation of GSK2592984A vaccine at a 21-day interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive 2 doses of a placebo at a 21-day interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 2 doses of a formulation of GSK2340274A vaccine at a 21-day interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 2 doses of a formulation of GSK2340273A vaccine at a 21-day interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' investigational vaccine GSK2590066A</intervention_name>
    <description>Intramuscular injection, two doses</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' investigational vaccine GSK2592984A</intervention_name>
    <description>Intramuscular injection, two doses</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' investigational vaccine GSK2340274A</intervention_name>
    <description>Intramuscular injection, two doses</description>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' investigational vaccine GSK2340273A</intervention_name>
    <description>Intramuscular injection, two doses</description>
    <arm_group_label>Group F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection, two doses</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who the investigator believes can and will comply with the requirements of&#xD;
             the protocol.&#xD;
&#xD;
          -  Written informed consent obtained from the subject.&#xD;
&#xD;
          -  Male and female adults, 18-49 years of age at the time of the first vaccination.&#xD;
&#xD;
          -  Satisfactory baseline medical assessment by history and physical examination.&#xD;
&#xD;
          -  Safety laboratory test results within the parameters specified in the protocol.&#xD;
&#xD;
          -  Access to a consistent means of telephone contact&#xD;
&#xD;
          -  Female subjects of non-childbearing potential may be enrolled in the study. Female&#xD;
             subjects of childbearing potential may be enrolled in the study, if the subject: has&#xD;
             practiced adequate contraception for 30 days prior to vaccination, and has a negative&#xD;
             urine pregnancy test on the day of first vaccination, and has agreed to continue&#xD;
             adequate contraception during the entire treatment period and for 2 months after&#xD;
             completion of the vaccination series.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history of physician-confirmed infection with an H5N1 virus.&#xD;
&#xD;
          -  Increased risk of occupational exposure to H5N1 influenza viruses.&#xD;
&#xD;
          -  Previous vaccination at any time with an H5N1 vaccine, or with an oil-in water&#xD;
             adjuvanted influenza vaccine.&#xD;
&#xD;
          -  Planned administration of an adjuvanted influenza vaccine or an H5N1 pandemic vaccine&#xD;
             during the entire study period.&#xD;
&#xD;
          -  Use of any investigational or non-registered product other than the study vaccine(s)&#xD;
             within 30 days preceding the first dose of study vaccine, or planned use during the&#xD;
             study period.&#xD;
&#xD;
          -  Presence of significant acute or chronic, uncontrolled medical or psychiatric illness.&#xD;
&#xD;
          -  Presence of neurological or psychiatric diagnoses which, although stable, are deemed&#xD;
             by the investigator to render the potential subject unable/unlikely to provide&#xD;
             accurate safety reports.&#xD;
&#xD;
          -  Evidence of current substance abuse, including alcohol, by medical history.&#xD;
&#xD;
          -  Presence of a temperature &gt;= 38.0ºC (≥100.4ºF), or acute symptoms greater than &quot;mild&quot;&#xD;
             severity on the scheduled date of first dose.&#xD;
&#xD;
          -  Diagnosed with cancer, or treatment for cancer, within 3 years. Persons with a history&#xD;
             of cancer who are disease-free without treatment for 3 years or more are eligible.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on&#xD;
             medical history and physical examination.&#xD;
&#xD;
          -  Receipt of systemic glucocorticoids within 1 month prior to study enrollment, or any&#xD;
             other cytotoxic or immunosuppressive drug within 6 months of study enrollment.&#xD;
&#xD;
          -  Receipt of any immunoglobulins and/or any blood products within 3 months of study&#xD;
             enrollment or planned administration of any of these products during the study period.&#xD;
&#xD;
          -  Any significant disorder of coagulation or treatment with warfarin derivatives or&#xD;
             heparin. Persons receiving individual doses of low molecular weight heparin, outside&#xD;
             of 24 hours prior to dosing, are eligible. Persons receiving prophylactic antiplatelet&#xD;
             medications.&#xD;
&#xD;
          -  An acute evolving neurological disorder or history of Guillain-Barré syndrome.&#xD;
&#xD;
          -  Administration of an inactivated seasonal influenza vaccine within 14 days before the&#xD;
             first study vaccine dose, or of any other vaccine(s) not foreseen by the study&#xD;
             protocol within 30 days before the first study vaccine dose. The administration of&#xD;
             live attenuated trivalent seasonal influenza virus vaccine (LAIV) is allowed.&#xD;
&#xD;
          -  Planned administration of any vaccine(s) not foreseen by the study protocol through&#xD;
             completion of the Day 42 visit. The administration of LAIV is allowed.&#xD;
&#xD;
          -  Any known or suspected allergy to any constituent of influenza vaccines or to latex,&#xD;
             or history of severe reaction to a previous influenza vaccination.&#xD;
&#xD;
          -  Known pregnancy or a positive urine beta-human chorionic gonadotropin (β-hCG) test&#xD;
             result prior to the first study vaccine dose.&#xD;
&#xD;
          -  Lactating or nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>November 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2010</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>H5N1</keyword>
  <keyword>Influenza</keyword>
  <keyword>Pandemic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114371</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114371</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114371</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114371</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114371</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114371</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

